Skip to content

Efficacy and safety of remimazolam for obese patients with different weight-based dosing strategies during anesthetic induction: a randomized clinical trial

Efficacy and safety of remimazolam for obese patients with different weight-based dosing strategies during anesthetic induction: a randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088152
Enrollment
Unknown
Registered
2024-08-13
Start date
2024-08-13
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obseity

Interventions

Adjusted body weight group:General anesthesia was induced by continuous intravenous infusion of remimazolam tosylate at a rate of 12 mg/kg/h based on the adjusted body weight.
Total body weight group:General anesthesia was induced by continuous intravenous infusion of remimazolam tosylate at a rate of 12 mg/kg/h based on the total body weight.
Lean body weight group:General anesthesia was induced by continuous intravenous infusion of remimazolam tosylate at a rate of 12 mg/kg/h based on the lean body weight.

Sponsors

The Second Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18~65 years old. 2.ASA class I to II. 3. An elective operation is planned for intuotracbation under general anesthesia and establishing venous access in the upper limb. 4.BMI=30kg/m2. 5.Mallampati class I to II. 6. Informed consent signed by the patient himself or his legally authorized representative.

Exclusion criteria

Exclusion criteria: 1. Cardiopulmonary disease, severe cardiac insufficiency (preoperative LVEF<50% or NYHA Grade IV), severe liver dysfunction (Child-Pugh Grade C), severe renal dysfunction (requiring dialysis treatment). 2.The preoperative medication regimen comprises benzodiazepines and opioids. 3. With a history of difficult airway (modified Mallampati score level III or IV) or difficult tracheal intubation, selective awake fiber tracheal intubation is planned. 4.History of neurological or psychiatric disorders or utilization of psychotropic medications. 5. Patients who used remimazolam and experimental anesthetics with caution or contraindication. 6.Received general anesthesia within 14 days prior to enrollment or had participated in other drug clinical trials within the preceding 3 months.

Design outcomes

Primary

MeasureTime frame
The success rate of general anesthesia induction;

Secondary

MeasureTime frame
The incidence of adverse events during anesthesia induction;Consumption of remimazolam tosylate ;The correlation betweenTBW,ABW,LBW, and consumption of remimazolam tosylate;Hemodynamic parameters during anesthesia induction (heart rate, blood pressure);the minimum pulse oxygen saturation;The bispectral index;The time of loss of consciousness;

Countries

China

Contacts

Public ContactXin Zhao

Department of Anesthesiology, the Second Hospital, Cheeloo College of Medicine, Shandong University

lujnzx@sohu.com+86 176 6008 5551

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026